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2Abstract 
Four Schiff bases derived from 7-hydrazin-yl-5,8-dihydroindolo[2,3-d][2]benzazepin-
(6H)-one and its bromo-substituted analogue (HL1–HL4) and four copper(II) 
complexes 1–4 have been synthesised and fully characterised by standard 
spectroscopic methods (1H and 13C NMR, UV–vis), ESI mass spectrometry, single 
crystal X-ray diffraction and spectroelectrochemistry. In addition, two previously 
reported complexes with paullone ligands 5 and 6 were prepared and studied for 
comparison reasons. The CuII ion in 1–4 is five-coordinate and adopts a square-
pyramidal or slightly distorted square-pyramidal coordination geometry. The ligands 
HL1–4 act as tridentate, the other two coordination places are occupied by two 
chlorido co-ligands. The organic ligands in 2 and 3 are bound tighter to copper(II) 
when compared to related paullone ligands in 5 and 6. The new compounds show 
very strong cytotoxic activity against human colon adenocarcinoma doxorubicin-
sensitive Colo 205 and multidrug resistant Colo 320 cancer cell lines with IC50 values 
in low micromolar to nanomolar concentration range. 
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3Introduction
Indolobenzazepines are a class of compounds with a broad spectrum of biological 
activities, amongst them analgesic, antidepressant, antimalarial, antidiabetic, 
anticancer and antiparasitic.1–7 The search for potent kinase inhibitors led to 
indolo[3,2-d]benzazepines, known as paullones.8 Cyclin dependent kinases (cdks) 
are attractive targets for anticancer drugs, since they control the cell cycle.9 Research 
on structure-activity relationships (SARs) showed that electron-withdrawing groups in 
position 9 of the paullone scaffold (Chart 1, left) enhance the cdk inhibition, while the 
lactam moiety is essential for the anticancer activity. This finding resulted in the 
discovery of the lead compounds kenpaullone and alsterpaullone (Chart 1).10  
Despite their potency, paullones possess some adverse properties. In particular, the 
low aqueous solubility and bioavailability hampered their clinical use. Later it was 
shown that the bioavailability can be improved by the attachment of suitable metal 
binding sites onto the paullone backbone and the consequent metal complex 
formation with gallium(III), ruthenium(II), osmium(II) and copper(II) ions. This led to 
highly cytotoxic compounds with an enhanced aqueous solubility with copper(II) 
complexes being the most active ones.11–16 However, cdks seem not to be the main 
target for these metal complexes.17 Alternative mechanisms of action have been 
suggested, amongst them DNA intercalation.14
In our present work, we focused our attention on the isomeric indolo[2,3-
d]benzazepine scaffold (Chart 1, right). It differs from the paullone core by the 
position of the lactam group in the azepine ring and features a flipped indole moiety 
with respect to the benzazepinone half of the molecule. These new compounds 
contain a typical latonduine structural motif. Latonduine-modified molecules usually 
exhibit prominent anticancer activity in vitro, along with the ability to inhibit tubulin 
polymerisation.18–21 Like paullones, these compounds do not possess any metal 
binding site. Therefore, it was of interest to us to chemically modify them and obtain 
proligands with potentially tridentate κN, κN’, κN’’ metal binding site, in particular, for 
copper(II). Copper is an essential trace metal and therefore considered to be safer 
than other metals used in chemotherapy, i.e. platinum.22,23 In addition, it is well-
established that copper(II) is able to strongly enhance the cytotoxicity of biologically 
active ligands.24
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R
R = Br (kenpaullone)
R = NO2 (alsterpaullone)
Chart 1. The indolo[3,2-d]benzazepinone (paullone) (left), vs the indolo[2,3-
d]benzazepinone backbone (right) with numbering schemes.
Herein we report on the synthesis and characterisation of four novel latonduine core 
containing proligands and their copper(II) complexes. In order to obtain structure-
activity relationships we modified the indolobenzazepine backbone by inserting a 
bromine substituent at position 11, the equivalent to position 9 in the paullone 
scaffold (compare kenpaullone). In addition, an aldehyde and a ketone containing a 
functional group in a position suitable for chelate formation were used for Schiff base 
condensation reactions, namely 2-formyl- and 2-acetylpyridine (Chart 2). 
The new compounds have been characterised by 1H and 13C NMR spectroscopy 
(HL1–HL4), single crystal X-ray diffraction (HL4, 1–4) and ESI mass spectrometry; 
their purity was validated by elemental analysis. Solution equilibrium properties of 
HL3 and its copper(II) complex 3 were characterised in DMSO-water mixture by UV–
vis titrations.  The cytotoxicity of the proligands and the corresponding copper(II) 
complexes was tested in Colo 205 (chemo sensitive) and Colo 320/MDR-LRP 
(multidrug resistant) human colon adenocarcinoma cell lines and one non-cancerous 
human embryonal lung fibroblast MRC-5 cell line and compared to those of the two 
previously reported paullone-derived copper(II) complexes 5 and 6 (Chart 3).15,25 The 
new compounds showed very high activity with IC50 values from the low micromolar 
to the nanomolar concentration range and were superior to 5 and 6 in cancer cell 
lines, while less cytotoxic in non-cancerous MRC-5 cells. Furthermore some 
selectivity for cancer cells over normal cells was observed in most cases, making this 
compound class pertinent for further development as anticancer drugs. 
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NH
S
(ii)
N
H
N
NH
(ii
i)
N
H
NH
N N
R2
N
R1 R1 R1
H2N
R1
R1 = H (A)
R1 = Br (B)
R1 = H (C)
R1 = Br (D)
R1 = H (E)
R1 = Br (F)
R1 = R2 = H (HL1)
R1 = Br, R2 = H (HL2)
R1 = H, R2 = CH3 (HL3)
R1 = Br, R2 = CH3 (HL4)
N
H
N
HN N N
Cu
ClCl
R1
R1 = R2 = H (1)*
R1 = Br, R2 = H (2)
R1 = H, R2 = CH3 (3)
R1 = Br, R2 = CH3 (4)
R2
(iv)
Chart 2. New proligands and copper(II) complexes synthesised in this work.a 
Underlined numbers indicate compounds studied by X-ray diffraction. *1 crystallized 
from DMF as the trimer [Cu3Cl4(HL1)3]Cl2 (1trim). aReagents and conditions: (i) C: 
phosphorus pentasulfide/aluminum oxide, acetonitrile, 85 °C, overnight; D: 
phosphorus pentasulfide/aluminum oxide, tetrahydrofuran, 75 °C, overnight; (ii) 
hydrazine monohydrate, reflux, overnight; (iii) HL1, HL2: 2-formypyridine, ethanol, 85 
°C, overnight; HL3, HL4: 2-acetylpyridine, ethanol, 85 °C, overnight; (iv) CuCl2·2H2O, 
isopropanol, reflux, 15 min.  
N
H
N
HNR
1
N
N
Cu Cl
Cl
R2
R1 = Br, R2 = H (5)
R1 = H, R2 = CH3 (6)
Chart 3. Paullone derived copper(II) complexes used in this study.15,25
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6Experimental
2-Iodobenzonitrile, ethyl-1H-indole-carboxylate and 5-bromo-ethyl-1H-indole-
carboxylate were purchased from ABCR. Borane solution (1M in THF), absolute 
DMF, dimethylaminopyridine, di-tert-butyl-dicarbonate, absolute acetonitrile, 
palladium(II) acetate, sodium bicarbonate, basic aluminuim oxide, 2-acetylpyridine 
and 2-formylpyridine were bought from Fisher/Acros Organics. Ethoxy-methylchloride 
was obtained form TCI. Sodium hydride, phosphorus(V) sulfide, celite, hydrazine 
monohydrate and methyl iodide were purchased from Sigma Aldrich, while lithium 
hydroxide monohydrate and triphenylphosphine were from Alfa Aesar. 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide-hydrochloride was purchased from IRIS biotech. 
Silver(I) carbonate was purchased from Merck. 2-Iodobenzylamine was prepared by 
a known method.26 The unsubstituted indolo[2,3-d]benzazepinone (A) was prepared 
by following published protocols.18–20 The 11-bromo-substituted B was prepared 
using reported precedures,18–20 with some modifications, a detailed description of the 
synthesis of B is given in the Supplementary Information file.
Synthesis of proligands
5,8-dihydroindolo[2,3-d][2]benzazepin-7(6H)-thione (C). 5,8-dihydroindolo[2,3-
d][2]benzazepin-7(6H)-one (A) (966 mg, 3.88 mmol) was dissolved in absolute 
acetonitrile (77 mL) in a Schlenk tube under argon atmosphere. A mixture of 
phosphorus(V) pentasulfide and basic aluminium oxide (0.6 : 1 w/w)27 (1.60 g) was 
added and the reaction mixture was stirred at 90 °C overnight. The next day, the 
mixture was cooled to room temperature and filtered. The filtrate was concentrated in 
vacuo and taken up in water (50 mL). The pH was adjusted to 8 using saturated 
potassium carbonate solution. The solution was extracted with dichloromethane 
(DCM) (3 × 100 mL). The organic phases were combined and dried over magnesium 
sulfate. The dried organic phase was concentrated and the raw product was purified 
on silica using a mixture of DCM : methanol 99 : 1 as eluent. Yield: 841 mg, 82%. 1H 
NMR (500 MHz, DMSO-d6) δ 11.78 (s, 1H, NH), 10.57 (t, J = 5.5 Hz, 1H, NH), 7.98 
(dd, J = 14.4, 7.9 Hz, 2H, H(Ar)), 7.64 (d, J = 8.3 Hz, 1H, H(Ar)), 7.53 (t, J = 7.5 Hz, 1H, 
H(Ar)), 7.48 (d, J = 6.9 Hz, 1H, H(Ar)), 7.41 (t, J = 7.3 Hz, 1H, H(Ar)), 7.36 (t, J = 7.4 Hz, 
1H, H(Ar)), 7.20 (t, J = 7.5 Hz, 1H, H(Ar)), 4.41 – 4.28 (m, 1H, CH2), 4.04 (d, J = 12.2 
Hz, 1H, CH2). ESI-MS (acetonitrile/methanol + 1% water), positive: m/z 265.08 [M + 
H]+.
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711-bromo-5,8-dihydroindolo[2,3-d][2]benzazepin-7(6H)-thione (D). 5,8-
dihydroindolo[2,3-d][2]benzazepin-7(6H)-one (B) (1.00 g, 3.06 mmol) and a mixture 
of phosphorus(V) pentasulfide and basic aluminium oxide (0.6 : 1 w/w)27 (2.20 g) 
were suspended in dry THF (50 mL) in an 100 mL Schlenk tube, under argon 
atmosphere. The reaction mixture was stirred overnight at 75 °C. The next day it was 
cooled to room temperature, the yellow precipitate was filtered off and washed with 
THF. The filtrate was evaporated and the residue was purified on silica by using 
DCM/methanol 99 : 1 as eluent. The product as yellow-orange powder was obtained 
after removal of the solvent. Yield: 635 mg, 60%. 1H NMR (500 MHz, DMSO-d6) δ 
12.00 (s, 1H, NH), 10.67 (t, J = 5.6 Hz, 1H, NH), 8.10 (d, J = 1.7 Hz, 1H, H(Ar)), 7.93 
(d, J = 7.2 Hz, 1H, H(Ar)), 7.60 (d, J = 8.7 Hz, 1H, H(Ar)), 7.55 (td, J = 7.5, 1.4 Hz, 1H, 
H(Ar)), 7.51 – 7.47 (m, 2H, H(Ar)), 7.43 (td, J = 7.4, 1.1 Hz, 1H, H(Ar)), 4.33 (s, 1H, CH2), 
4.06 (d, J = 12.5 Hz, 1H, CH2). ESI-MS (acetonitrile/methanol + 1% water), positive, 
m/z 344.99 [M + H]+.
7-hydrazin-yl-5,8-dihydroindolo[2,3-d][2]benzazepin-(6H)-one (E). A suspension 
of 5,8-dihydroindolo[2,3-d][2]benzazepin-7(6H)-thione (C) (582 mg, 2.21 mmol) in 
hydrazine monohydrate (8 mL) under argon atmosphere was refluxed overnight. On 
the next day it was cooled to room temperature and the pale yellow precipitate was 
filtered off, washed with water and dried in vacuo. Yield: 496 mg, 86%. 1H NMR (500 
MHz, DMSO-d6) δ 11.43 (s, 1H, NH), 7.86 (t, J = 8.5 Hz, 2H, H(Ar)), 7.49 – 7.40 (m, 
2H, H(Ar)), 7.37 (d, J = 6.5 Hz, 1H), H(Ar), 7.20 (dt, J = 21.5, 7.3 Hz, 2H, H(Ar)), 7.09 (t, 
J = 7.0 Hz, 1H, H(Ar)), 6.32 (s, 1H, NH), 5.00 (s, 2H, NH2), 4.07 (s, 2H, CH2). ESI-MS 
(acetonitrile/methanol + 1% water), positive: m/z 263.09 [M + H]+.
11-bromo-7-hydrazin-yl-5,8-dihydroindolo[2,3-d][2]benzazepin-(6H)-one (F). A 
suspension of 11-bromo-5,8-dihydroindolo[2,3-d][2]benzazepin-7(6H)-thione (D) (830 
mg, 2.42 mmol) in hydrazine monohydrate (20 mL) under argon atmosphere was 
refluxed overnight. On the next day it was cooled to room temperature and the pale 
yellow precipitate was filtered off, washed with water and dried in vacuo. Yield: 757 
mg, 92%. 1H NMR (500 MHz, DMSO-d6) δ 7.97 (d, J = 1.8 Hz, 1H, H(Ar)), 7.80 (d, J = 
7.2 Hz, 1H, H(Ar)), 7.47 – 7.37 (m, 3H, H(Ar)), 7.33 – 7.29 (m, 1H, H(Ar)), 7.25 (td, J = 
7.4, 1.0 Hz, 1H, H(Ar)), 6.36 (s, 1H, NH), 5.07 (s, 2H, NH2), 4.06 (s, 2H, CH2). ESI-MS 
(acetonitrile/methanol + 1% water), positive: m/z 343.24 [M + H]+.
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8HL1·0.4C2H5OH. A solution of 7-hydrazin-yl-5,8-dihydroindolo[2,3-d][2]benzazepin-
(6H)-one (E) (199 mg, 0.76 mmol) in ethanol (3 mL) in a 25 mL Schlenk tube was 
degassed by bubbling argon through the solution for 10 min. 2-Formylpyridine (79 µL, 
0.83 mmol) was added and the mixture was stirred overnight at 85 °C. The next day 
the reaction mixture was cooled to room temperature and the solvent was 
evaporated. The residue was taken up in water (10 mL) and ethanol was added until 
complete dissolution. Then, the solvent was removed slowly under reduced pressure 
until precipitation started. The mixture was allowed to stand at 4 °C overnight. The 
next day, a yellow precipitate was filtered off, washed with water/ethanol 2:1 and 
dried in vacuo. Yield: 266 mg, 99%. Anal. Calcd for C22H17N5·0.4C2H5OH (M 372.13 
g mol–1): C, 73.71; H, 5.07, N, 19.09. Found: C, 73.91; H, 5.33; N, 18.82. 1H NMR 
(600 MHz, DMSO-d6) δ 11.93 (s, 1H, H12), 8.59 (d, J = 4.1 Hz, 1H, H18), 8.37 (d, J = 
8.0 Hz, 2H, H15, H21), 8.31 (t, J = 5.4 Hz, 1H, H6), 7.98 (dd, J = 15.4, 7.6 Hz, 2H, H12, 
H3), 7.87 (td, J = 7.5, 1.2 Hz, 1H, H20), 7.60 (d, J = 8.2 Hz, 1H, H9), 7.53 – 7.49 (m, 
1H, H2), 7.47 (d, J = 6.6 Hz, 1H, H4), 7.40 – 7.31 (m, 3H, H10, H1, H19), 7.20 (dd, J = 
11.1, 4.0 Hz, 1H, H11), 4.36 – 4.02 (m, 2H, H5). 13C NMR (151 MHz, DMSO) δ 155.62 
(Cq, C7), 154.52 (Cq, C16), 152.14 (CH, C15), 149.28 (CH, C18), 137.78 (Cq, C4a), 
136.76 (Cq, C8a), 136.30 (CH, C20), 133.161 (Cq, C12c), 129.01( Cq, C7a), 128.09 
(CH, C4), 128.06 (CH, C2), 127.41 (CH,C3), 126.33 (CH,C1), 124.94 (Cq, C12a), 
124.10(CH, C10), 123.87 (CH, C19), 120.77 (CH, C21), 120.46 (CH, C11), 120.22(CH, 
C12), 117.12(Cq, C12b), 112.69(CH, C9), 46.00 (CH2, C5). For atom numbering 
scheme see ESI†, Scheme S1. ESI-MS (acetonitrile/methanol + 1% water), positive: 
m/z 352.26 [M + H]+.
HL2·H2O. A solution of 11-bromo-7-hydrazin-yl-5,8-dihydroindolo[2,3-
d][2]benzazepin(6H)one (F) (370 mg, 1.08 mmol) in ethanol (6 mL) in a 25 mL 
Schlenk tube was degassed by bubbling argon through the solution for 10 min. 2-
Formylpyridine (113 µL, 1.19 mmol) was added and the mixture was stirred overnight 
at 85 °C. The next day the reaction mixture was cooled to room temperature and the 
solvent was removed under reduced pressure. The residue was dissolved in 
methanol (10 mL). This solution was concentrated under reduced pressure to about 
half the volume, when the formation of a yellow precipitate was observed. The 
resulting suspension was allowed to stand at 4 °C overnight. On the next day the 
precipitate was filtered off and washed with cold methanol. Yield: 135 mg, 31%. Anal. 
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9Calcd for C22H16BrN5·H2O (M 448.32 g mol–1): C, 58.93; H, 4.05, N, 15.62. Found: C, 
58.86; H, 3.97; N, 15.67. 1H NMR (700 MHz, DMSO-d6) δ 12.14 (s, 1H, H8), 8.59 (d, 
J = 4.6 Hz, 1H, H18), 8.38 – 8.35 (m, 2H, H15, H21), 8.32 (t, J = 5.3 Hz, 1H, H6), 8.10 
(d, J = 1.5 Hz, 1H, H12), 7.92 (d, J = 7.6 Hz, 1H, H1), 7.86 (dd, J = 11.0, 4.4 Hz, 1H, 
H20), 7.56 (d, J = 8.7 Hz, 1H, H9), 7.52 (t, J = 7.5 Hz, 1H, H2), 7.47 – 7.44 (m, 2H, 
H10, H4), 7.39 – 7.34 (m, 2H, H19, H3), 4.46 – 3.99 (m, 2H, H5). 13C NMR (176 MHz, 
DMSO-d6) δ 155.25 (Cq, C7), 154.40 (Cq, C16), 152.52 (CH, C15), 149.29 (CH, C18), 
137.86 (Cq, C4a), 136.30 (CH, C20), 135.39 (Cq, C8a), 132.95 (Cq, C12), 130.29 (Cq, 
C7a), 128.27 (CH, C4), 128.17 (CH, C2), 127.35 (CH, C1), 126.71 (CH, C10), 126.63 
(CH. C3), 126.54 (Cq, C12a), 123.95 (CH, C19), 122.23 (CH, C12), 120.82 (CH, C21), 
116.48 (Cq, C12b), 114.70 (CH, C9), 113.01 (Cq, C11), 45.91 (CH2, C5). For atom 
numbering scheme see ESI†, Scheme S1. ESI-MS (acetonitrile/methanol + 1% 
water), positive: m/z 432.06 [M + H]+.
HL3. A solution of 7-hydrazin-yl-5,8-dihydroindolo[2,3-d][2]benzazepin(6H)one (E) 
(200 mg, 0.76 mmol) in ethanol (3.5 mL) in a 25 mL Schlenk tube was degassed by 
bubbling argon through the solution for 10 min. 2-Acetylpyridine (94 µL, 0.84 mmol) 
was added and the mixture was stirred overnight at 86 °C.  The next day the reaction 
mixture was cooled to room temperature and stored at 4 °C for 2 h. The yellow 
precipitate was filtered off and washed with cold ethanol. Yield: 261 mg, 94%. Anal. 
Calcd for C23H19N5 (M 365.43 g mol–1): C, 75.59; H, 5.24, N, 19.16. Found: C, 75.32; 
H, 5.05; N, 19.00. 1H NMR (600 MHz, DMSO-d6) δ 11.77 (s, 1H, H8), 8.62 – 8.55 (m, 
1H, H18), 8.50 (d, J = 8.0 Hz, 1H2), 8.02 – 7.91 (m, 3H, H1, H5, H12), 7.81 (td, J = 7.8, 
1.8 Hz, 1H, H20), 7.62 (d, J = 8.2 Hz, 1H, H9), 7.49 (td, J = 7.6, 1.2 Hz, 1H, H2), 7.43 
(d, J = 6.8 Hz, 1H, H4), 7.40 – 7.29 (m, 3H, H3, H19, H10), 7.19 (dt, J = 18.3, 5.5 Hz, 
1H, H11), 4.64 – 3.75 (m, 2H, H5), 2.50 (s, 3H, H22 (overlapped DMSO signal)). 13C 
NMR (151 MHz, DMSO-d6) δ 158.23 (Cq, C15), 156.45 (Cq, C16), 153.36 (Cq, C7), 
148.44 (CH, C18), 137.95 (Cq, C4a), 136.65 (Cq, C8a), 135.88 (CH, C20), 133.74 (Cq, 
C12c), 129.75 (Cq, C7a), 128.07 (CH, C4), 127.97 (CH, C2), 127.33 (CH, C1), 126.18 
(CH, C3), 125.05 (Cq, C12a), 123.92 (CH, C10), 123.52 (CH, C19), 120.84 (CH, C21), 
120.37 (CH, C11), 120.13 (CH, C12), 116.50 (Cq, C12b), 112.62 (CH, C9), 45.97 (CH2, 
C5) 13.08 (CH3, C22). For atom numbering scheme see ESI†, Scheme S1. ESI-MS 
(acetonitrile/methanol + 1% water), positive: m/z 366.16 [M + H]+.
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HL4. A solution of 11-bromo-7-hydrazin-yl-5,8-dihydroindolo[2,3-
d][2]benzazepin(6H)one (F) (76 mg, 0.22 mmol) in ethanol (2 mL) in a 10 mL Schlenk 
tube was degassed by bubbling argon through the solution for 10 min. 2-
Acetylpyridine (27 µL, 0.24 mmol) was added and the mixture was stirred overnight 
at 85 °C.  The next day the reaction mixture was cooled to room temperature and 
allowed to stand at 4 °C for 2 days. The yellow-brown plates of X-ray diffraction 
quality were filtered off and washed with cold ethanol. Yield: 57 mg, 58%. Anal. Calcd 
for C23H18BrN5 (M 444.33 g mol–1): C, 62.17; H, 4.08, N, 15.76. Found: C, 61.86; H, 
4.13; N, 15.74. 1H NMR (600 MHz, DMSO-d6) δ 11.98 (s, 1H, H8), 8.60 – 8.56 (m, 1H, 
H18), 8.53 – 8.44 (m, 1H, H21), 8.09 (d, J = 1.8 Hz, 1H, H12), 7.99 (t, J = 5.3 Hz, 1H, 
H6), 7.93 – 7.90 (m, 1H, H1), 7.82 (ddd, J = 8.0, 7.5, 1.8 Hz, 1H, H20), 7.58 (d, J = 8.7 
Hz, 1H, H9), 7.54 – 7.49 (m, 1H, H2), 7.47 – 7.42 (m, 2H, H10, H4), 7.38 – 7.33 (m, 
2H, H19, H3), 4.39 – 4.08 (m, 2H, H5), 2.49 (s, 3H, H22 (overlapped DMSO signal)). 
13C NMR (151 MHz, DMSO-d6) δ 158.62 (Cq, C15), 156.34 (Cq, C16), 152.96 (Cq, 
C7), 148.45 (CH, C18), 138.04 (Cq, C4a), 135.91 (CH, C20), 135.30 (Cq, C8a), 133.08 
(Cq, C12c), 131.02 (Cq, C7a), 128.20 (CH, C4), 128.15 (CH, C2), 127.28 (CH, C1), 
126.68 (Cq, C12a), 126.53 (CH, C10), 126.49 (CH, C19), 123.61 (CH, C3), 122.14 (CH, 
C12), 120.88 (CH, C21), 115.90 (Cq, C12b), 114.65 (CH, C9), 112.92 (Cq, C11), 45.88 
(CH2, C5), 13.10 (CH3, C22). For atom numbering scheme see ESI†, Scheme S1. 
ESI-MS (acetonitrile/methanol + 1% water), positive: m/z 446.08 [M + H]+.
Synthesis of copper(II) complexes
1·0.4H2O·0.7C3H7OH. To a solution of HL1 (169 mg, 0.48 mmol) in isopropanol (8 
mL) a solution of CuCl2·2H2O (82 mg, 0.48 mmol) in methanol (0.5 mL) was added. 
The reaction mixture was heated to reflux for 15 min, cooled down and allowed to 
stand at 4 °C overnight. The product was filtered off, washed with isopropanol and 
dried in vacuo to give a green-brown powder. Yield: 232 mg, 99%. Anal. Calcd for 
C22H17Cl2CuN5·0.4H2O·0.7C3H7OH (M 535.13 g mol–1): C, 53.86; H, 4.24, N, 13.08. 
Found: C, 54.09; H, 4.41; N, 13.08. Solubility in water/1% DMSO ≥ 1.0 mg mL–1. ESI-
MS (acetonitrile/methanol + 1% water), positive: m/z 764.23 [CuII(L1)(HL1) ]+. 
2·0.5H2O. To a solution of HL2 (100 mg, 0.23 mmol) in isopropanol (20 mL) at 70 °C 
a solution of CuCl2·2H2O (40 mg, 0.23 mmol) in methanol (1 mL) was added. The 
colour of the solution changed from yellow to green and the reaction mixture was 
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refluxed for 15 min. After cooling down the solution was kept at 4 °C overnight. Green 
precipitate was filtered off, washed with isopropanol and dried in vacuo. Yield: 105 
mg, 77%. Anal. Calcd for C22H16BrCl2CuN5·0.5H2O (M 573.76 g mol–1): C, 46.05; H, 
2.99, N, 12.21. Found: C, 45.93; H, 2.86; N, 12.52. Solubility in water/1% DMSO ≥ 
0.7 mg mL–1. ESI-MS (acetonitrile/methanol + 1% water), positive: m/z 922.07 
[CuII(L2)(HL2) ]+.
3·0.3H2O·0.6C3H7OH. To a solution of HL3 (200 mg, 0.55 mmol) in isopropanol (140 
mL) at 70 °C a solution of CuCl2·2H2O (95 mg, 0.55 mmol) in methanol (1 mL) was 
added. The colour of the solution changed from yellow to green and the mixture was 
refluxed for 15 min. After cooling down the solution was kept at 4 °C overnight. The 
next day a green precipitate was filtered off, washed with isopropanol and dried in 
vacuo. Yield: 224 mg, 82%. Anal. Calcd for C23H19Cl2CuN5·0.3H2O·0.6C3H7OH (M 
541.34 g mol–1): C, 55.02; H, 4.54, N, 12.94. Found: C, 55.07; H, 4.16; N, 12.84. 
Solubility in water/1% DMSO ≥ 0.3 mg mL–1. ESI-MS (acetonitrile/methanol + 1% 
water), positive: m/z 463.04 [CuCl(HL3)]+, 427.07 [Cu(L3)]+.
4·0.5H2O. To a solution of HL4 (50 mg, 0.11 mmol) in isopropanol (20 mL) at 70 °C 
CuCl2·2H2O (19 mg, 0.11 mmol) in methanol (1 mL) was added. The colour of the 
solution changed from yellow to green and the reaction mixture was refluxed for 15 
min. After cooling to room temperature, the solution was kept at 4 °C overnight. The 
next day a green precipitate was filtered off, washed with isopropanol and dried in 
vacuo. Yield: 51 mg, 80%. Anal. Calcd for C23H18BrCl2CuN5·0.5H2O (M 587.79 g 
mol–1): C, 47.00; H, 3.26, N, 11.91. Found: C, 46.85; H, 3.53; N, 11.81. Solubility in 
water/1% DMSO ≥ 0.9 mg mL–1. ESI-MS (acetonitrile/methanol + 1% water), positive: 
m/z 542.96 [CuIICl(HL4)]+, 507.00 [CuII(L4)]+.
Crystallographic Structure Determination. X-ray diffraction quality single crystals 
of HL4 were obtained by crystallisation from ethanol, 1trim·2DMF·1.25H2O, 
3·1.2DMF·0.25H2O, 3´·DMF and 4·2DMF by slow diffusion of diethyl ether into the 
DMF solution of the corresponding complex, while 2·0.55MeOH by slow evaporation 
of the metanolic solution of the compound. The measurements were performed on 
Bruker X8 APEXII CCD (2·0.55MeOH, 3·1.2DMF·0.25H2O) and Bruker D8 Venture 
(HL4, 1trim ·2DMF·1.25H2O, 3´·DMF, 4·2DMF) diffractometers. Single crystals were 
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positioned at 27, 27, 27, 35, 25 and 27 mm from the detector, and 672, 1632, 1000, 
614, 479 and 1566 frames were measured, each for 8, 30, 10, 24, 3 and 6 s over 0.4, 
0.5, 0.5, 0.7, 0.5 and 0.5° scan width for HL4, 1trim ·2DMF·1.25H2O, 2·0.55MeOH, 
3·1.2DMF·0.25H2O, 3´·DMF and 4·2DMF, respectively. The data were processed 
using SAINT software.28 Crystal data, data collection parameters, and structure 
refinement details are given in Tables 1 and 2. The structures were solved by direct 
methods and refined by full-matrix least-squares techniques. Non-H atoms were 
refined with anisotropic displacement parameters. H atoms were inserted in 
calculated positions and refined with a riding model. Co-crystallised solvent 
molecules (DMF, H2O or CH3OH) were found to be disordered in 1trim, 2 and 3. The 
positional parameters of disordered atoms were refined by using PART, DFIX, SADI 
and EADP tools implemented in SHELX. The following computer programs and 
hardware were used: structure solution, SHELXS-2014 and refinement, SHELXL-
2014;30 molecular diagrams, ORTEP;31 computer, Intel CoreDuo. CCDC 
1903184‒1903189.
Spectrophotometric solution equilibrium studies. An Agilent Carry 8454 diode 
array spectrophotometer was used to record the UV‒vis spectra in the interval 200–
800 nm. The path length was 2 cm. Spectrophotometric titrations were performed on 
samples containing the proligand HL3 or the complex 3 at 12.5 M concentration by a 
KOH solution in the presence of 0.1 M KCl in DMSO : water 30 : 70 (w/w) mixture as 
solvent at 25.0 ± 0.1 oC in the pH range from 2 to 11. An Orion 710A pH-meter 
equipped with a Metrohm combined electrode (type 6.0234.100) and a Metrohm 665 
Dosimat burette were used for the pH measurements and titrations. The electrode 
system was calibrated to the pH = −log[H+] scale in the DMSO-water solvent mixture 
by means of blank titrations (HCl vs. KOH) similarly to the method suggested by 
Irving et al. in pure aqueous solutions.32 The average water ionisation constant (pKw) 
was 14.52 ± 0.05, which corresponds well to the literature data.33 Argon was passed 
over the solutions during the titrations. Proton dissociation constants (pKa) of the 
ligand, overall stability constants (log) of the copper(II) complexes and the individual 
spectra of the various species present in solution were calculated by the computer 
program PSEQUAD.34  MpLqHr) is defined for the general equilibrium pM + qL + rH 
MpLqHr as  (MpLqHr) = [MpLqHr]/[M]p[L]q[H]r where M denotes the copper(II) ion 
and L the completely deprotonated ligand. The calculations were always made from 
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the experimental titration data measured in the absence of any precipitate in the 
solution.
Distribution coefficients (D7.4) values of HL1, HL3 and complexes 1, 3 were attempted 
to be determined by the traditional shake-flask method in n-octanol/buffered aqueous 
solution at pH 7.40 (20 mM phosphate buffer, 0.10 M KCl) as described previously.35
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Table 1. Crystal data and details of data collection for HL4, 1trim ·2DMF·1.25H2O, 2·0.55MeOH, 3·1.2DMF·0.25H2O 
Compound HL4 1trim ·2DMF·1.25H2O 2·0.55MeOH 3·1.2DMF·0.25H2O
empirical formula C23H18BrN5 C72H67.5Cl6Cu3N17O3.25 C22.55H18.2BrCl2CuN5O0.55 C26.6H27.9Cl2CuN6.2O1.45
fw 444.33 1626.25 582.37 592.09
space group P21/c P-1 C2/c P-1
a [Å] 18.405(4) 13.0443(3) 37.232(30) 9.7602(13)
b [Å] 8.2958(16) 14.9957(3) 11.3330(11) 13.4027(15)
c [Å] 13.230(3) 20.2999(4) 11.6674(10) 20.685(2)
 [°] 92.0747(8) 98.235(4)
 [°] 103.962(8) 103.4914(8) 107.494(3) 92.013(5)
 [°] 112.4054(8) 93.367(4)
V [Å3] 1960.4(7) 3535.02(13) 4695.3(7) 2670.7(5)
Z 4 2 8 4
 [Å] 0.71073 0.71073 0.71073 0.71073
calcd [g cm-3] 1.506 1.528 1.648 1.473
crystal size [mm] 0.10  0.08  0.01 0.14  0.08  0.06 0.13  0.10  0.02 0.80  0.08  0.08
T [K] 100(2) 100(2) 100(2) 296(2)
 [mm‒1] 2.117 1.183 2.883 1.053
R1[a] 0.0527 0.0387 0.0599 0.0725
wR2[b] 0.1203 0.0984 0.1650 0.1719
GOF[c] 1.041 1.033 1.148 0.943
a R1 = ||Fo|  |Fc||/|Fo|. b wR2 = {[w(Fo2  Fc2)2]/[w(Fo2)2]}1/2. c GOF = {[w(Fo2  Fc2)2]/(n  p)}1/2, where n is the number of 
reflections and p is the total number of parameters refined. 
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Table 2. Crystal data and details of data collection for 3´·DMF and 4·2DMF
Compound 3´·DMF 4·2DMF
empirical formula C26H25ClCuN6O C29H32BrCl2CuN7O2
fw 536.51 724.97
space group P21/c P-1
a [Å] 10.3347(4) 12.0530(9)
b [Å] 23.4454(7) 16.7234(14)
c [Å] 11.0757(4) 17.8152(15)
 [°] 105.698(3)
 [°] 117.731(1) 105.962(3)
 [°] 106.665(3)
V [Å3] 2375.41(14) 3060.2(4)
Z 4 4
 [Å] 0.71073 0.71073
calcd [g cm-3] 1.500 1.574
crystal size [mm] 0.10  0.08  0.05 0.19  0.08  0.03
T [K] 100(2) 100(2)
 [mm‒1] 1.065 2.234
R1[a] 0.0566 0.0498
wR2[b] 0.1597 0.1177
GOF[c] 1.031 1.024
a R1 = ||Fo|  |Fc||/|Fo|. b wR2 = {[w(Fo2  Fc2)2]/[w(Fo2)2]}1/2. c GOF = {[w(Fo2  
Fc2)2]/(n  p)}1/2, where n is the number of reflections and p is the total number of 
parameters refined. 
Cyclic voltammetry and spectroelectrochemistry. Cyclic voltammetric 
experiments with 0.5 mM solutions of 1–4 in 0.1 M nBu4NPF6 (puriss quality from 
Fluka; dried under reduced pressure at 70 °C for 24 h before use) supporting 
electrolyte in DMSO (SeccoSolv max. 0.025% H2O, Merck) were performed under 
argon atmosphere using a three-electrode arrangement with platinum wire as counter 
electrodes, and silver wire as pseudoreference electrode. Glassy carbon (GC) or 
platinum wire served as working electrodes. Ferrocene purchased from Sigma 
Aldrich was used as the internal potential standard without further purification. All 
potentials in voltammetric studies were quoted vs ferricenium/ferrocene (Fc+/Fc) 
redox couple. A Heka PG310USB (Lambrecht, Germany) potentiostat with a 
PotMaster 2.73 software package served for the potential control in voltammetric 
studies. In situ ultraviolet-visible-near-infrared (UV‒vis‒NIR) spectroelectrochemical 
measurements were performed on a spectrometer (Avantes, Model AvaSpec-
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2048x14-USB2 in the spectroelectrochemical cell kit (AKSTCKIT3) with the Pt-
microstructured honeycomb working electrode, purchased from Pine Research 
Instrumentation. The cell was positioned in the CUV-UV Cuvette Holder (Ocean 
Optics) connected to the diode-array UV-vis-NIR spectrometer by optical fibers. UV-
vis-NIR spectra were processed using the AvaSoft 7.7 software package. Halogen 
and deuterium lamps were used as light sources (Avantes, Model AvaLight-DH-S-
BAL).
Cell lines. Human colonic adenocarcinoma cell lines Colo 205 doxorubicin-sensitive 
(ATCC-CCL-222) and Colo 320/MDR-LRP multidrug resistant over-expressing 
ABCB1 (MDR1)-LRP (ATCC-CCL-220.1) were purchased from LGC Promochem, 
Teddington, UK. The cells were cultured in RPMI 1640 medium supplemented with 
10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 1 mM Na-pyruvate and 
10 mM HEPES. The cell lines were incubated at 37 °C, in a 5% CO2, 95% air 
atmosphere. The semi-adherent human colon cancer cells were detached with 
Trypsin-Versene (EDTA) solution for 5 min at 37 °C. MRC-5 human embryonal lung 
fibroblast cell line (ATCC CCL-171) was purchased from LGC Promochem, 
Teddington, UK. The cells were cultured in Eagle’s Minimal Essential Medium 
(EMEM, containing 4.5 g/L glucose) supplemented with a non-essential amino acid 
mixture, a selection of vitamins and 10% heat-inactivated fetal bovine serum. The cell 
lines were incubated at 37 °C, in a 5% CO2, 95% air atmosphere. 
Assay for cytotoxic effect. MRC-5 non-cancerous human embryonic lung fibroblast 
and human colonic adenocarcinoma cell lines (doxorubicin-sensitive Colo 205 and 
multidrug resistant Colo 320 colonic adenocarcinoma cells) were used to determine 
the effect of compounds on cell growth. The effects of increasing concentrations of 
compounds on cell growth were tested in 96-well flat-bottomed microtiter plates. The 
compounds were dissolved in DMSO and stock solutions of 10 mM were prepared. 
These were further diluted in the appropriate cell culture medium by 2-fold serial 
dilution starting from 100 µM to 0.195 µM. The adherent human embryonal lung 
fibroblast cells were cultured in 96-well flat-bottomed microtiter plates, using EMEM 
supplemented with 10% heat-inactivated fetal bovine serum. The density of the cells 
was adjusted to 1104 cells in 100 μL per well, the cells were seeded for 24 h at 37 
C, 5% CO2, then the medium was removed from the plates containing the cells, and 
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the dilutions of compounds previously made in a separate plate were added to the 
cells in 200 μL. In case of the colonic adenocarcinoma cells, the two-fold serial 
dilutions of compounds were prepared in 100 μL of RPMI 1640, horizontally. The 
semi-adherent colonic adenocarcinoma cells were treated with Trypsin-Versene 
(EDTA) solution. They were adjusted to a density of 1104 cells in 100 μL of RPMI 
1640 medium, and were added to each well, with the exception of the medium 
control wells. The final volume of the wells containing compounds and cells was 200 
μL. The culture plates were incubated at 37 °C for 72 h; at the end of the incubation 
period, 20 μL of MTT (thiazolyl blue tetrazolium bromide, Sigma) solution (from a 
stock solution of 5 mg/mL) were added to each well. After incubation at 37 °C for 4 h, 
100 μL of sodium dodecyl sulfate (SDS) (Sigma) solution (10% in 0.01 M HCI) were 
added to each well and the plates were further incubated at 37˚C overnight. Cell 
growth was determined by measuring the optical density (OD) at 540/630 nm with 
Multiscan EX ELISA reader (Thermo Labsystems, Cheshire, WA, USA). Inhibition of 
the cell growth was determined according to the formula below:
IC50  = 100100 




controlmediumODcontrolcellOD
controlmediumODsampleOD
Results are expressed in terms of IC50, defined as the inhibitory dose that reduces 
the growth of the cells exposed to the tested compounds by 50%. The IC50 values 
were calculated using GraphPad Prism7 software. 
Results and Discussion
Synthesis. The synthesis of the main core structure A in Chart 2 was performed by 
following the published literature protocols. B was synthesised similarly.18–20 A 
detailed description for the synthesis of B is given in the ESI†. The lactam derivatives 
A and B were converted into thiolactams C and D by reaction with P2S5 on Al2O3 in 
dry boiling acetonitrile or tetrahydrofuran in 82 and 60% yield, respectively.27 
Thionation with phosphorus pentasulfide bound to aluminium oxide offers the 
advantage that the reagent can be removed by filtration after the reaction. In addition, 
this method was chosen because the standard method for the thionation of 
paullones10 gave only small yields. Further reaction of C and D with hydrazine 
hydrate as reagent and solvent afforded hydrazines E and F in 86 and 92% yield, 
respectively. It should be noted that that F exists in two tautomeric forms in DMSO 
solution, as evidenced by the appearance of two signal sets in the 1H NMR spectrum. 
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The predominant species is the one shown in Chart 2 where N13 is protonated and 
the double bond is endocyclic. The NMR signal of N13H appears as a singlet at δ = 
6.36 ppm. In the minor species, (ca. 15% in DMSO), N6 is protonated and the double 
bond is exocyclic. N6H appears as a triplet with the typical coupling constant of 5.3 
Hz at δ = 8.49 ppm. NMR data is given only for the major species in the experimental 
part, because of the low signal intensity of the minor species and signal overlapping. 
For atom numbering scheme see Scheme S1, ESI†. Similar tautomerism has been 
observed in the case of paullones previously.14 The Schiff bases HL1–HL4 were 
prepared in 99, 31, 94 and 58% yield, respectively, from hydrazine species E and F 
and 2-formyl- and 2-acetylpyridine taken in 10% excess in boiling ethanol. 1H and 13C 
NMR spectra of HL1–HL4 were in agreement with the formulae proposed. Notably, 
HL4 showed a second set of NMR-signals with an intensity of about 10% of the main 
species in DMSO-d6. Tautomerism as in the case for F was excluded, because of the 
presence of the typical triplet signal for N6H in both species. It is likely that a mixture 
of E and Z isomers is present, similarly to previously reported paullone derived 
ruthenium(II) and osmium(II) complexes.17 However, low signal intensity and signal 
overlapping did not allow a more accurate analysis to be performed. ESI mass 
spectra measured in positive ion mode showed peaks with m/z 352.26, 432.06, 
366.16 and 446.08 attributed to [M+H]+. The purity of HL1–HL4 (>95%) was 
confirmed by elemental analysis. The structure of HL4 was also established by single 
crystal X-ray diffraction (vide infra). Complexes 1‒4 were prepared by reaction of 
HL1–HL4 in isopropanol by addition of a methanolic solution of CuCl2·2H2O in 1:1 mol 
ratio, respectively, in 77 to 99% yields. The positive ion ESI mass spectrum of 1 
showed the presence of a peak with m/z 764.18 due to [CuII(L1)(HL1)]+. The mass 
spectra of 2–4 contain peaks at m/z 528.97 and 492.99, 463.04 and 427.07, 542.96 
and 507.00 attributed to [CuIICl(HL2–4)]+ and [CuII(L2–4)]+, respectively. The elemental 
analysis was in agreement with the structures shown in Chart 2, providing the 
required purity of bulk samples for biological investigations. The complexes 1‒4 as 
well as 3´ have been studied by X-ray diffraction.
X-ray Diffraction. The results of X-ray diffraction studies for 1trim, 2, 3, 3´, 4 and HL4 
are shown in Figures 1–3, respectively, with selected bond lengths and bond angles 
quoted in the legends. Complex 1 crystallised as a trimer (1trim), while 2–4 and 3´as 
monomeric entities. The corresponding ligand is protonated in 1trim, 2–4 and acts as 
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a tridentate one being coordinated to copper(II) via azepine nitrogen, hydrazine 
nitrogen and pyridine nitrogen atoms. The ligands can be deprotonated in the 
presence of a base. In particular, deprotonation of HL3 in 3 in the presence of 
triethylamine was confirmed by X-ray diffraction study of 3´ (Figure 2b). The 
coordination geometry of copper(II) ion in the trimer (1trim) and in mononuclear 
complexes 2–4 is square-pyramidal or distorted square-pyramidal (see legends to 
Figures 1-3 quoting 5-descriptor values36 for each copper(II) ion), while in 3´ it is 
slightly distorted square-planar. The coordination polyhedron in each case is 
completed by two or one chlorido co-ligands. Note that the same coordination 
geometry was previously established for complexes 5 and 6 with paullone derivatives 
(5 = 0.10 (5) and 0.05 (6)).15 The bond lengths Cu–N5 = 2.038(3) and 2.0220(15), 
Cu–N14 = 1.982(3) and 1.9787(15), Cu–N17 = 2.062(3) and 2.0466(15) in 5 and 6, 
respectively, are significantly longer than those in 2 and 3 (see legends to Figures 1 
and 2) by 0.01–0.05 and 0.005–0.04 Å, respectively, even though the metal binding 
moieties in the corresponding ligands are closely related. Overall a tighter binding of 
the ligand moiety in 2 and 3 is to be mentioned when compared to that in 5 and 6. 
The proligand HL4 and the ligand HL4 in 4 adopt different configurations and distinct 
proton tautomeric forms as shown in Figure 3 and confirmed by the distribution of 
bond lengths (electron density) over the fragment C5–N6–C7–N13–N14–C15 quoted 
in the legend to Figure 3.    
Page 19 of 35 Dalton Transactions
D
al
to
n
Tr
an
sa
ct
io
ns
A
cc
ep
te
d
M
an
us
cr
ip
t
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
0 
M
ay
 2
01
9.
 D
ow
nl
oa
de
d 
on
 5
/1
4/
20
19
 5
:5
2:
00
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
DOI: 10.1039/C9DT01238A
20
Figure 1. ORTEP views of a) the complex cation [Cu3Cl4(HL1)3]2+ in 1trim and b) of 
[CuCl2(HL2)] in 2. Selected bond distances (Å) and bond angles (deg) in 1trim: Cu1–
N6 1.994(2), Cu1–N14 1.991(2), Cu1–N17 2.044(2), Cu1–Cl1 2.2685(8), Cu1–Cl2 
2.4382(8), N6–Cu1–N14 78.75(10), N14–Cu1–N17 77.92(9), Cu2–N27 1.990(2), 
Cu2–N35 1.975(2), Cu2–N38 2.034(2), Cu2–Cl2 2.4492(8), Cu2–Cl3 2.2781(8), 
N27–Cu2–N35 79.39(10), N35–Cu2–N38 78.63(10), Cu3–N48 1.995(3), Cu3–N56 
1.959(2), Cu3–N59 2.044(2), Cu3–Cl3 2.6404(8), Cu3–Cl4 2.2116(8), N48–Cu3–N56 
79.51(10), N56–Cu3–N59 79.20(10). Details of coordination geometry in 1trim: 5 
(Cu1) = 0.35, 5 (Cu2) = 0.25, 5 (Cu3) = 0.17; in 2: Cu–N6 1.982(5), Cu–N14 
1.971(5), Cu–N17 2.051(5), Cu–Cl1 2.2252(16), Cu–Cl2 2.5762(17), N6–Cu–N14 
79.7(2), N14–Cu–N17 78.8(2). Details of coordination geometry in 2: 5 (Cu) = 0.06.  
Of note is also that the two Cu–Cl bonds in 1–4 are markedly different. The bond 
length from copper(II) to basal chlorido co-ligand is by 0.17 to 0.43 Å shorter 
compared to that between copper(II) and the apical chlorido co-ligand. A similar 
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situation is also typical for 5 and 6 reported previously.15,25 The corresponding bonds 
differ by 0.19 and 0.13 Å in 5 and 6, respectively.
Figure 2. ORTEP views of a) one crystallographically independent complex 
[CuCl2(HL3)] in 3 (co-crystallised solvent is omitted) and b) of [CuCl(L3)] in 3´. 
Selected bond distances (Å) and bond angles (deg) in 3: Cu1–N6 1.979(4), Cu1–N14 
1.973(4), Cu1–N17 2.034(4), Cu1–Cl1 2.2460(12), Cu1–Cl2 2.4567(14), N6–Cu1–
N14 78.72(17), N14–Cu1–N17 78.33(16), Cu2–N28 1.986(5), Cu2–N36 1.969(4), 
Cu2–N39 2.031(4), Cu2–Cl3 2.2309(14), Cu2–Cl4 2.5054(13), N28–Cu2–N36 
79.09(18), N36–Cu2–N39 78.36(18). Details of coordination geometry in 2: 5 (Cu1) 
= 0, 5 (Cu2) = 0.06 (second crystallographically independent molecule); in 3´: Cu–N6 
1.937(3), Cu–N14 1.953(3), Cu–N17 2.019(3), Cu–Cl 2.2058(9), N6–Cu–N14 
79.52(12), N14–Cu–N17 80.27(12).   
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Figure 3. ORTEP views of a) proligand HL4 and b) of [CuCl2(HL4)] in 4 (co-
crystallised solvent is omitted). Selected bond distances (Å) and bond angles (deg) in 
HL4: C5–N6 1.459(4), N6–C7 1.344(4), C7–N13 1.325(4), N13–N14 1.391(3), N14–
C15 1.300(4); in 4: Cu1–N6 2.011(2), Cu1–N14 1.986(2), Cu1–N17 2.057(3), Cu1–
Cl1 2.2612(8), Cu1–Cl2 2.4327(9), C5–N6 1.470(4), N6–C7 1.295(4), C7–N13 
1.376(4), N13–N14 1.366(3), N14–C15 1.285(4), N6–Cu–N14 78.83(10), N14–Cu–
N17 77.34(10), Cu2–N28 2.010(2), Cu2–N36 1.968(2), Cu2–N39 2.035(3), Cu2–Cl3 
2.2204(8), Cu2–Cl4 2.5321(9), N28–Cu2–N36 79.40(10), N36–Cu2–N39 78.40(10). 
Details of coordination geometry in 4: 5 (Cu1) = 0.28, 5 (Cu2) = 0.28 (second 
crystallographically independent molecule).    
Solution equilibrium studies. The proligand HL3 and complex 3 (Charts 1 and 2) 
were chosen for the detailed solution equilibrium studies. Two complexes with HL3 
were obtained in the solid state, namely [CuCl2(HL3)] (3) and [CuCl(L3)] (3´) (Figure 
2), in which the ligand adopts different protonation states. We therefore aimed to 
study the transformation process of 3 into 3´ in solution. Both HL3 and complex 3 
have fairly poor water solubility, thus UV–vis spectrophotometric titrations were 
performed in the presence of 30% (w/w) DMSO at low concentration (12.5 M). The 
UV–vis spectra recorded for the proligand revealed small but characteristic changes 
upon increasing the pH (Figure 4a) and two well separated proton dissociation 
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processes could be observed. The first deprotonation process was accompanied by 
a blue shift (max: 351 nm → 340 nm) and an absorbance increase at ~ 440 nm in the 
pH range between 2.5 and 3.25. The solution was yellow in this pH range. Upon 
increasing the pH the solution became colourless due to the decrease of absorbance 
in the visible wavelength range (415–490 nm) and the max is red shifted (340 nm → 
360 nm). At pH > 6.5 precipitation occurred in the solution most likely due to the 
formation of the neutral species, thus data collected below this pH were used for the 
calculations. The pKa values (Table 3) and the spectra of the individual ligand 
species (Figure 5a) were calculated on the basis of deconvolution of recorded UV–
vis spectra. The proligand HL3, which can be drawn in two tautomeric forms due to 
the rearrangement of the N=C-NH-N and NH-C=N-N bonds, contains two additional 
protons in its fully protonated form (H2(HL3)2+, (Chart 4). The first deprotonation 
process (pKa1) can presumably be attributed to deprotonation of the pyridinium 
nitrogen, while the second step (pKa2) to the deprotonation of the benzazepinium 
nitrogen. The pKa values were predicted by using the software MarvinSketch as 
well37 (Table 3), showing the same order of the stepwise deprotonation processes as 
we suggest herein. However, these are somewhat different compared to the values 
obtained experimentally in the DMSO-water solvent mixture.  
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Figure 4. UV–vis spectra recorded for a) HL3 and b) complex 3 at various pH values 
in 30–70% (w/w) DMSO-water solvent mixture. {cligand= ccomplex = 12.5 µM; T = 298 K; 
I = 0.10 M (KCl); l = 2 cm}.
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H
NH
NH
N HN
N
H
NH
NH
N N
N
H
N
NH
N N
N
H
NH
N
N N
H2(HL3)2+ H(HL3)+
HL3 tautomerism
Ka1 Ka2
Chart 4. Stepwise deprotonation processes of the fully protonated form of HL3 and its 
tautomeric forms.
The UV–vis spectrum recorded for 3 at pH ~2 (Figure 4b) showed significant complex 
formation comparing to that of the free proligand. Thus the complex dissociates only 
partly under these conditions. Therefore, the tridentate coordination via the (N, N, N) 
donor set is assumed in [Cu(HL3)]2+ at such low pH. Upon increasing the pH the max 
is shifted to the lower wavelength (338 nm → 323 nm) concomitant with the 
development of a new band with max 444 nm implying a rearrangement in the 
copper(II) chromophore. Most probably the non-coordinating hydrazinic nitrogen is 
deprotonated, as is the case with 3´ (Figure 2b). In addition a novel process starts at 
pH > 7 as the max shows a further bathochromic shift (max ~483 nm). Although it is 
accompanied by remarkable absorbance decrease in the whole wavelength range 
monitored due to the formation of precipitate of a neutral mixed hydroxido species 
[Cu(L3)(OH)]. On the basis of the recorded UV–vis spectra overall stability constants 
for the complexes [Cu(HL3)]2+ and [Cu(L3)]+ were computed (Table 3) in addition to 
their individual spectra (Figure 5a), while log for [Cu(L3)(OH)] could be only 
estimated. Concentration distribution curves were computed using the determined 
stability constants (Figure 5b) revealing the predominant formation of [Cu(L3)]+ at 
neutral pH. 
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Figure 5. a) Molar absorbance spectra computed for proligand HL3 and complex 3 in 
the various protonation states, and concentration distribution curves for 3 plotted 
against the pH. (Dashed lines show the region where precipitate appears.) {ccomplex = 
12.5 µM; T = 298 K; I = 0.10 M (KCl); 30% (w/w) DMSO-H2O}.
The lipo-hydrophilic character is an important property of drugs as it strongly affects 
the passage via biological membranes. Therefore we attempted to determine the 
logD7.4 values for proligands HL1, HL3 and complexes 1, 3 using the traditional 
shake-flask method in n-octanol/buffered aqueous solution at pH 7.40. All these 
compounds were found to be so lipophilic that data could not be obtained 
experimentally since they remained in the octanol phase and only a minor fraction 
was found in the aqueous phase. Thus logD7.4 values were estimated for proligands 
HL1, HL3 by using the software MarvinSketch as well37 (Table 3). The predicted 
values indicate the strong lipophilic character of the compounds. The bromo 
substituents in HL2, HL4 are suggested to increase the lipophilicity even more.           
Table 3. Proton dissociation constants (Ka) of HL3 and overall stability constants () 
of its copper(II) complexes determined by UV–vis titrations in 30–70% (w/w) DMSO-
water solvent mixture, {T = 298 K; I = 0.10 M (KCl)}. Predicted pKa and logD7.4 values 
for HL3 and HL1 by the software MarvinSketch.37  
constant predicted constant
pKa1 H2(HL3)2+ 2.51±0.01 pKa1 H2(HL3)2+ 1.82
pKa2 H(HL3)+ 5.03±0.01 pKa2 H(HL3)+ 5.37
log [Cu(HL3)]2+ 10.96±0.02 logD7.4 HL3 +4.03
log [Cu(L3)]+ 6.39±0.02 pKa1 H2(HL1)2+ 2.00
log [Cu(L3)(OH)] ~ -1.9 pKa2 H(HL1)+ 5.39
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pKa [Cu(HL3)]2+ 4.57 logD7.4 HL1 +4.75
pKa [Cu(L3)]+ ~ 8.3
Electrochemistry and spectroelectrochemistry. Cyclic voltammograms of 1–4 in 
DMSO/nBu4NPF6 at glass carbon (GC) working electrode show two irreversible 
reduction peaks with cathodic peak potentials at Epc1 = ‒0.75 V and Epc2 = ‒1.13 V for 
1, Epc1 = ‒0.68 V and Epc2 = ‒1.05 V for 2, Epc1 = ‒0.74 V and Epc2 = ‒1.12 V for 3 and 
Epc1 = ‒0.76 V and Epc2 = ‒1.11 V for 4 vs Fc+/Fc (see Figure 6a and Figure S1, 
ESI†). The first irreversible reduction step can be attributed to the Cu(II) → Cu(I) 
process. We suppose that unstable [Cu(I)L] complex decomposes with partial or full 
release of the proligand. The follow-up product is then irreversibly reduced in the next 
reduction step. 
-1.2 -1.0 -0.8 -0.6 -0.4 -0.2
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
0.3
I /
 A
E vs Fc+/Fc / V
-1.4 -1.2 -1.0 -0.8 -0.6 -0.4 -0.2
-0.2
-0.1
0.0
0.1
0.2
0.3
 I 
/ 
A
 E / V vs. Fc+/Fc
(a)
(b)
Figure 6. Cyclic voltammograms of (a) 1 and (b) 4 in DMSO/nBu4NPF6 at scan rate 
of 100 mV s–1 at GC working electrode (black traces represent the first scan, while 
red traces the second scan).
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To check the chemical reversibility of the first reduction step for 1–4, the in situ 
spectroelectrochemical UV-vis-NIR experiments were carried out under an argon 
atmosphere in a special thin layer spectroelectrochemical cell with a microstructured 
honeycomb working electrode. The UV–vis spectra measured upon cathodic 
reduction of 1 revealed in the region of the first reduction peak a new emerging 
optical band at 385 nm. In addition, a decrease of the intensity of the bands at 275 
and 485 nm is observed (Figure 7a). According to the findings of the UV–vis titrations 
(Figure 5a), these spectral changes suggest the dissociation of the Cu(II) complex 
and the liberation of the proligand.
(a)
300 400 500 600 700
0.0
0.2
0.4
0.6
0.8
1.0
A
 / nm
300 400 500 600 700 800
0.0
0.2
0.4
0.6
0.8
 / nm
CV scan
(b)
-1.2 -0.8 -0.4
-0.8
0.0
0.8
I /
 A
E vs Fc+/Fc / V
Figure 7. In situ UV-vis-NIR spectroelectrochemistry for 1 in DMSO/nBu4NPF6 (scan 
rate of 10 mV s−1, Pt-microstructured honeycomb working electrode): (a) evolution of 
UV−vis spectra in 2D projection in forward scan in the region of the first reduction 
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peak; (b) UV–vis spectra detected simultaneously upon the cyclic voltammetric scan 
in 3D projection (Inset: the corresponding cyclic voltammogram).
Very similar spectroelectrochemical response was observed also for 2–4 in the 
region of the first reduction peak as illustrated for 3 in Figure S2, ESI†. However, 
upon scan reversal the product that is formed upon reduction (Cu(II) to Cu(I)) is not 
reoxidised back to the initial state (Figure 7b). This fact provides strong evidence that 
the Cu(I) oxidation state is unstable, resulting in the partial or complete 
decomposition of the complex. The presence of the Cu(II) ion in the cells may lead to 
the production of ROS in vivo because of Cu(II)/Cu(I) redox cycling due to Fenton 
like reactions.38,39
Cytotoxic activity assays. The latonduine derivatives HL1–HL4, their copper(II) 
complexes 1–4 , and the paullone derived copper(II) complexes 5, 6 exhibited strong 
cytotoxic activity in cancer cells, exceeding tremendously that of cisplatin. The 
latonduine derivatives HL1–HL4 revealed strong cytotoxic activity in cancer cells, 
while they were less toxic in non-cancerous MRC-5 fibroblasts showing selectivity 
towards cancer cells (Table 4).
Table 4. The IC50 values for latonduine derivatives HL1–HL4 and their copper(II) 
complexes 1–4 , as well as for copper(II) complexes with paullones 5, 6. *Selectivity 
factors (SFs) for Colo 205 and Colo 320 cancer cell lines over non-cancerous MRC-5 
cells. SF(205) = IC50 MRC-5/IC50 Colo 205, SF(320) = IC50 MRC-5/IC50 Colo 320.
 IC50 (µM),a 72 h
 Colo 205 Colo 320 MRC-5 SF(205)* SF(320)*
HL1 0.266 ±  0.012 0.294 ± 0.005 1.522 ± 0.547 6 5
HL2 0.189 ± 0.040 0.051 ± 0.012 2.312 ± 0.032 12 45
HL3 0.037 ± 0.004 0.042 ± 0.001 0.127 ± 0.004 3 3
HL4 0.017 ± 0.002 0.018 ± 0.005 1.257 ± 0.463 74 70
1 0.346 ± 0.008 0.315 ± 0.023 0.461 ± 0.069 - -
2 0.556 ± 0.028 0.104 ± 0.002 0.378 ± 0.004 - 4
3 0.017 ± 0.001 0.020 ± 0.001 0.162 ± 0.009 10 8
4 0.007 ± 0.001 0.015 ± 0.002 0.201 ± 0.001 29 13
5 1.704 ± 0.218 0.413 ± 0.044 0.152 ± 0.001 - -
6 0.380 ± 0.032 0.120 ± 0.007 0.061 ± 0.003 - -
Cisplatin 31.94 ± 2.17 4.81 ± 0.68 12.41 ± 0.367 - 3
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Interesting structure-activity and selectivity relationships deserve to be mentioned. 
Acetylpyridine derived proligands HL3 and HL4 were by one order of magnitude more 
cytotoxic than formylpyridine derived HL1 and HL2. Bromo substituted HL2 and HL4 
were about twice as cytotoxic compared to their unsubstituted counterparts HL1 and 
HL3. The bromo substituted proligands HL2 and HL4 were not only more active, but 
they also showed a more pronounced selectivity for cancer cells over normal cells, by 
a factor of 2 to 25 compared to unsubstituted analogues HL1 and HL3 (see Table 4). 
Interestingly HL2 is more active in the multidrug resistant Colo 320 cell line than in 
the chemosensitive Colo 205 cell line with selectivity factors of 45 vs 12, respectively. 
The most active proligand, HL4, shows IC50 values in the nanomolar range and is 
around 70 times more toxic in the cancer cell lines (Colo 205, Colo 320) than in the 
normal fibroblast MRC-5 cell line. 
Formylpyridine derived copper(II) complexes 1 and 2 showed activity comparable to 
the respective proligands HL1 and HL2, however, their selectivity for cancer cells over 
non-cancerous cell line is diminished. Copper(II) complex 2 was more active in the 
chemoresistant Colo 320 cancer cell line than in the chemosensitive Colo 205 cell 
line, similar to HL2, leading to the assumption that proligand HL2 and copper(II) 
complex 2 may interfere with the ABCB1 transporter (P-glycoprotein). This is the first 
characterised ATP-binding cassette (ABC) transporter, which is the most studied 
member of this protein superfamily. ABC transporters bind and hydrolyse ATP to 
provide energy needed to transport/extrude the substrates/drugs via the cell 
membranes. It has been shown that the overexpression of this protein is often 
associated with the development of multidrug resistance phenotype in cancer and 
disadvantageous clinical prognosis.40 An emerging research approach is the use of 
efflux pump inhibitors as adjuvant compounds (so-called “chemosensitizers”) to 
improve the efficacy of antitumour therapy, by co-administering them with 
chemotherapeutic agents. Computer-aided drug design techniques are used for the 
rapid assessment of chemical libraries in order to guide and speed up the early-stage 
development of new active compounds. In order to determine the ability of the 
compounds investigated in the present study to interact with P-glycoprotein 
molecular docking calculations based on crystallographic data reported by Ferreira et 
al.41 will be performed and the results will be reported in due course. 
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Acetylpyridine derived complexes 3 and 4 are by one to two orders of magnitude 
more active than their formylpyridine derived analogues 1 and 2 and about twice as 
cytotoxic as the corresponding proligands HL3 and HL4. The strong enhancement of 
cytotoxicity, when a methyl group is present at the imine carbon of the ligand, has 
been observed also in the case of paullone derived copper(II) complexes 
previously.15,25 Compound 4 is the most active drug in the whole series, with an 
astonishingly low IC50 value of 7 nM in the Colo 205 cancer cell line, being superior to 
the corresponding proligand HL4 with IC50 value of 17 nM in the same cell line. The 
presence of bromo-substitutuent in position 9 of the paullone42 or similar position in 
latonduine derivative and ketimine group instead of aldimine one increases the 
cytotoxic activity of both proligands and metal complexes, but we do not have any 
explanation of this observation at the molecular level now. Even though 4 is more 
cytotoxic to MRC-5 cells than HL4, it still shows marked selectivity for cancer cells 
over normal ones, with selectivity factors of 29 and 13 for the Colo 205 and Colo 320 
cancer cell lines, respectively. Paullone derived complexes 5 and 6 are isomers of 
latonduine derived complexes 2 and 3. Intriguingly, 5 and 6 are less cytotoxic in the 
cancer cell lines (Colo 205, Colo 320) and more cytotoxic in MRC-5 cells, when 
compared to their counterparts 2 and 3. This means that the new latonduine derived 
copper(II) complexes presented in this work offer both enhanced activity and 
selectivity in comparison with previously reported paullone derivatives.   
Conclusions
Four new proligands which can be regarded as biologically active latonduine 
modified or isomeric to paullone derivatives and containing a potentially tridentate 
metal binding site, HL1–HL4 were prepared via a multistep synthesis. In addition, four 
copper(II) complexes 1–4 were synthesised by direct complex formation reactions of 
proligands with CuCl2·2H2O. For comparison two copper(II) complexes with paullone 
modified ligands reported previously, namely 5 and 6, were also used in this study. 
These two complexes form isomeric pairs with 2 and 3, respectively. The following 
features can be outlined from the performed investigations of the listed compounds. 
X-ray diffraction studies revealed, that like 5 and 6, complexes 1 – 4 are five-
coordinate and adopt a square-pyramidal or slightly distorted square-pyramidal 
coordination geometry. Deprotonation of the ligand HL3 in 3 resulted in formation of 
3´, in which a square-planar coordination geometry is adopted by copper(II) as 
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confirmed by single crystal X-ray crystallography. The decrease of coordination 
number of copper(II) from five in 3 to four in 3´ led to shortening of Cu–N and Cu–Cl 
bond lengths due to less repulsion between the ligand/donor atoms (see legend to 
Figure 2 for comparison of bond lengths in the two complexes). It should be also 
noted that the ligands HL2 and HL3 are bound stronger in terms of bond lengths to 
copper(II) when compared to those in isomeric paulone-based complexes 5 and 6, 
respectively. The Cu–N bond lengths were found to be by 0.01 – 0.05 and 0.005 – 
0.04 Å shorter in 2 and 3 than in 5 and 6, respectively. All the studied compounds are 
significantly lipophilic, and the proligands are in their neutral forms (HL) in solution at 
neutral pH (in 30% DMSO/H2O), while complexes are found in their [Cu(L)]+ forms 
under these conditions. 
Cell tests showed that the new proligands and copper(II) complexes are highly active 
against Colo 205 and Colo 320 cancer lines and show selectivity for cancer cell lines 
over MRC-5, a non-cancerous fibroblast cell line. Structure-activity relationships were 
established, revealing that a methyl substituent at the imine carbon leads to a distinct 
enhancement of the cytotoxicity of the new proligands and copper(II) complexes and 
that a bromo substituent at position 11 of the indolo[2,3-d]benzazepine backbone 
enhances the activity as well as the selectivity. Intriguingly, complexes 2 and 3 were 
by factors 3 and 22 and by factors 4 and 6 more cytotoxic against Colo 205 and Colo 
320 cells in terms of IC50 values than paullone-based complexes 5 and 6. In contrast, 
in non-cancerous cells 5 and 6 were more cytotoxic by factors 2.5 and 2.6 than 2 and 
3, respectively. So, the new complexes 2 and 3 appear to be superior to isomeric 
copper(II) complexes with paullone-modified ligands (5 and 6) in terms of suitability 
for further preclinical development as anticancer drugs.
 
Supporting Information
NMR numbering scheme for HL1–HL4 (Scheme S1), synthesis of B (Scheme S2), 
cyclic voltammograms of 2 and 3 (Figure S1), UV-vis-NIR spectroelectrochemistry for 
3 (Figure S2), NMR spectra (Figures S3–S20), ESI-MS spectra (Figures S21–S32). 
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